Effect of Aldosterone Blockade on Arterial Compliance

Effect of Aldosterone Blockade on Metabolic Parameters and Arterial Compliance

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01089309

Acronym

RAAS LAEI SAEI

Enrollment

Registered

2010-03-18

Start date

2004-05-31

Completion date

2007-06-30

Last updated

2010-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Elasticity, Arterial Stiffness

Keywords

Aldosterone Blockade, Arterial elasticity, Glycemic control

Brief summary

The present study investigated the long-term (12 months) effect of spironolactone treatment on glucose homeostasis, metabolic parameters and vascular properties.

Interventions

DRUGSpironolactone

Spironolactone orally, at a dose of 50 mg/day for 12 months

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

45 Years to 85 Years

Healthy volunteers

Inclusion criteria

1\. patients with type 2 diabetes mellitus

Exclusion criteria

1. history of unstable angina, myocardial infarction (MI), cerebrovascular accident (CVA) 2. major surgery within the six months preceding entrance to the study 3. unbalanced endocrine disease 4. any disease that might affect absorption of medications 5. plasma creatinine \>2.5 mg/dl 6. elevation of liver enzymes to more that twice the upper normal limit 7. plasma potassium levels \>5.5 mg/dl

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026